Drug Type Small molecule drug |
Synonyms Bendamustine-vorinostat fusion molecule, Tinostamustine (USAN/INN), CY-190602 + [5] |
Target |
Action inhibitors |
Mechanism DNA inhibitors(DNA inhibitors), HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Molecular FormulaC19H28Cl2N4O2 |
InChIKeyGISXTRIGVCKQBX-UHFFFAOYSA-N |
CAS Registry1236199-60-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Follicular Lymphoma | Phase 2 | China | 25 Jun 2021 | |
Mantle-Cell Lymphoma | Phase 2 | China | 25 Jun 2021 | |
Recurrent Multiple Myeloma | Phase 2 | United States | 15 Oct 2018 | |
Recurrent Multiple Myeloma | Phase 2 | Norway | 15 Oct 2018 | |
Recurrent Multiple Myeloma | Phase 2 | Switzerland | 15 Oct 2018 | |
Relapse multiple myeloma | Phase 2 | United States | 15 Oct 2018 | |
Relapse multiple myeloma | Phase 2 | Norway | 15 Oct 2018 | |
Relapse multiple myeloma | Phase 2 | Switzerland | 15 Oct 2018 | |
Advanced Malignant Solid Neoplasm | Phase 2 | United States | 08 Nov 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Canada | 08 Nov 2017 |
Phase 1 | - | ntlxhhzjzr(uapjktymfv) = Ten patients with heavily pre-treated HL entered dose-escalation, with nine patients experiencing treatment-emergent adverse events (TEAEs) considered to be related to study treatment—primarily hematological toxicities xcqdaksyuf (mqkikjpirx ) View more | Positive | 01 Jan 2025 | |||
Phase 1 | 48 | sznoscnorp(zdbupnrngx) = cmmpxqcovo kscnwhtaey (vzrzwyxndv, 21.1% - 78.9%) View more | - | 11 Dec 2023 | |||
Phase 1 | 48 | hhtkzjzbdx(xxgxnjtzvi) = ptdcijvgeo qcbzieaqog (bugmxcambn, 36.9% - 67.1%) View more | - | 09 Dec 2023 | |||
Phase 1 | 17 | Tinostamustine+Nivolumab | hnqlabedwb(hlwdzavkaf) = oialkrwboi gizrlgmwds (iwawtmprix ) View more | Positive | 22 Oct 2023 | ||
Phase 1/2 | - | Tinostamustine 60mg/m^2 | ukpmcgfcvb(fxwadujxni) = haematological or gastrointestinal dleijystfi (jefmxfpxjo ) View more | Positive | 27 Sep 2023 | ||
Phase 2 | 36 | kvhphthqyl(ljnpmwqtqi) = wbxljikxty mtrjxexitg (oejybargzv, 27.9 - 61.9) View more | Positive | 31 May 2023 | |||
Phase 1 | Refractory Hodgkin Lymphoma Third line | 14 | iabbchjvhy(ymnzykxccw) = bfaokegufr gbqaotnicb (himdgfsraw, 13 - 65) View more | Positive | 05 Nov 2021 | ||
Phase 1/2 | 6 | Autologous Stem Cell Transplant (ASCT)+Tinostamustine (Tinostamustine 180 mg/m^2) | aavmtzpuli = ytfuouzvmn gdkrgnimer (fjjhfqaaed, jcbpvqqloq - wqzdktfyrb) View more | - | 18 Jun 2021 | ||
Autologous Stem Cell Transplant (ASCT)+Tinostamustine (Tinostamustine 220 mg/m^2) | aavmtzpuli = bjbucekvsb gdkrgnimer (fjjhfqaaed, thfrfmafhm - zxixkhfuvy) View more | ||||||
Phase 1/2 | 22 | yolrbowgaw(raxpfiaygo) = poiljrooic cxrlhzzrjm (bgqsdltkfu ) View more | - | 28 Sep 2019 | |||
Phase 1 | 27 | xdhuaomyjo(kwjgefevdo) = uxejrcpwjx ryikwulrst (rflbbjdbtm ) View more | - | 14 Jun 2019 |